Key Clinical Message:
Renal involvement in SpA should not be missed, screening these patients during follow-up allows early detection of any impairment and helps guide early nephroprotection and treatment measures. AA amyloidosis, IgA nephropathy and urolithiasis are the most reported, however, other rare involvement can be described.